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Introduction
Autoimmune hemolytic anemia (AIHA) is a rare disease due
to the presence of antibodies directed against antigens on the
red blood cells (RBCs) surface. The estimated incidence in
adults is 1 to 3 in 100,000 per year with a peak age at 60 to
70 years.1 In two-thirds of the cases, autoantibodies are
polyclonal immunoglobulins (Ig) G and, as they react at
body temperature, they are named “warm” agglutinins.
Roughly half of warm-reactive AIHA (wAIHA) is primary,
while the other half is secondary, namely, associated with
lymphoproliferative syndromes, solid tumors, autoimmune
diseases, infections, or drugs.2 Signs and symptoms are
largely related to anemia. Management remains empirical
and is mainly based on the administration of corticoste-
roids.3 Although the association between AIHA and venous
thromboembolic events (VTE) is increasingly described in
the recent literature,4 to date, no guideline preconizes the
introduction of an antithrombotic prophylaxis nor the
screening for VTE in AIHA patients. Moreover, the thrombot-
ic risk in AIHA seems to be underestimated by clinicians.5
Here, we report the case of a 75-year-old man who
developed pulmonary embolism (PE) after being diagnosed
with idiopathic wAIHA and discuss the current knowledge
about thrombotic complications during AIHA.
Case Report
A 75-year-old man presented to the emergency room with
severe shortness of breath. Symptoms had been increasing
during the previous 4weeks, no triggering factorswere clearly
identified. Dyspnea progressively worsened to a NYHA-III
(New York Heart Association III) stage and was not associated
with cough nor fever. He had chest pain only under effort,
without palpitations, lower limb edema, or orthopnea. Three
days prior to admission, he developed severe generalized
weakness, dark-colored urine, and jaundice. His medical his-
tory was notable for well-controlled moderate chronic ob-
structive pulmonary disease (COPD; stage II according GOLD
[Global Initiative for Chronic Obstructive Lung Disease] classi-
fication) and for chronic ischemic heart disease for which he
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Vital signs on admission included temperature, 37°C;
pulse rate, 85 bpm; blood pressure, 131/75mm Hg; respira-
tory rate, 15/min; and oxygen saturation, 97% at ambient air.
Laboratory testing was notable for normochromic, macro-
cytic anemia with hemoglobin 83 g/L (reference range: 133–
177 g/L), absolute reticulocyte count of 614 109/L (reference
range: 20–120 109/L), total bilirubin of 154 μmol/L (refer-
ence range: 0–21 μmol/L), direct bilirubin of 13 μmol/L (refer-
ence range: 0–10 μmol/L), lactate dehydrogenase of 1,530 U/L
(reference range: 135–225 U/L), and undetectable serum
haptoglobin (reference range: 0.3–2.0 g/L). Direct antiglobulin
test (DAT) was strongly (4þ) reactive for warm IgG1 and IgG3.
Dipstick examination did not reveal the presence of hemoglobin
in theurine.Peripheralbloodsmearwascharacteristic, showinga
variousdegreeofanisocytosis, polychromasia,microspherocytes,
and few erythroblasts (►Fig. 1), and wAIHAwas diagnosed.
Workup for underlying causes of wAIHA, including thorac-
ic-abdominal computed tomography (CT) scan, serologic test-
ing for cytomegalovirus (CMV), Epstein–Barr virus (EBV), HIV,
viral hepatitis B and C, and screening for monoclonal gamm-
opathy, was negative. Of note, a concomitant autoimmune
condition was looked for and only low-titer (1/160) speckled
antinuclear antibodies without antibodies to chromatin or
extractable nuclear antigens were found. CT scan revealed
PE at a right laterobasal segmental and several bilateral sub-
segmental emboli without evidence of right cardiac overload
(no inversion of the right ventricle/left ventricle [RV/LV] ratio).
Cardiac enzymes were within normal ranges and echocardio-
gram showed both normal size and function of LV and RV. No
bilateral leg ultrasound was performed. Primary wAIHAwith
concomitant PE was diagnosed.
Given the history of ischemic heart disease, the patient
was transfused with 1 unit packed RBCs. High-dose oral
prednisone (1.5mg/kg per day) was prescribed. Because of
ongoing hemolytic anemia, two intravenous steroid pulses
(methylprednisolone of 125mg) were administered addi-
tionally on day 9. Given the segmental location of one lesion
andmany thrombotic risk factors involved (overweight, flare
of AIHA, and treatment with high-dose corticosteroids),
anticoagulation with rivaroxaban (15-mg twice daily for
the first 21 days, afterward 20-mg once a day [od]) was
prescribed. The patient was discharged home on day 13 with
corticosteroid tapering and rivaroxaban during active hemo-
lysis and for a minimum of 3 months.
Discussion
What Is the Risk, Incidence, and Prevalence of Venous
Thromboembolism in Autoimmune Hemolytic
Anemia?
Amonghospitalized patients, those admittedwith an immune-
mediated disease, including AIHA, are at an increased risk of
subsequentVTE.Ramagopalanet al studied the rate ratioofVTE
(deep vein thrombosis [DVT] and/or PE) of people admitted to
hospitalwith immune-mediateddiseases comparedwith three
references cohorts of hospitalized patients, constructed by
identifying the first admission for each individual with various
other, mainly minor medical and surgical conditions.6 They
found a rate ratio of respectively 2.83 (95% confidence interval
[CI]: 1.62–4.60,p< 0.001), 3.64 (2.11–5.85,p¼ 0.001), and3.83
(3.43–4.25, p< 0.001) for patients hospitalized for AIHA com-
paredwith controls in each cohort. Zöller et al analyzed the risk
for developing PE in patients hospitalized for autoimmune
disorders compared with the general Swedish population.
They found an incidence ratio (standardized for sex, age,
time, and comorbidity) of 11.07 (95% CI: 7.29–16.12) after
less than 1 year of follow-up, 3.73 for 1 to 5 years of follow-up
(95% CI: 2.58–5.22), 3.16 (95%CI: 1.87–5.00) for 5 to 10 years of
follow-up, and an overall incidence ratio of 3.44 (95% CI: 2.74–
4.26) for developing PE in patients hospitalized for AIHA.7
The risk of VTE occurrence among hospitalized adults
with selected autoimmune diseases, including AIHA, was
examined by Yusuf and colleagues in 2014.8 Based on almost
6,000,000 observations, they found that, when compared
with nonmaternal patients hospitalized without autoim-
mune disease, patients with AIHA had an adjusted odds ratio
for VTE occurring during or before hospitalization of 1.25
(95% CI: 1.05–1.49).8 Among patients with AIHA, immune
thrombocytopenic purpura, rheumatoid arthritis, or system-
ic lupus erythematosus, or>1 of these diseases, the risk of at
least one VTE event was 19.74, 7.72, 4.90, 9.89, and 13.35 per
1,000 person-years, respectively; among the comparison
group, the risk was 1.91 per 1,000 person-years.9
Amid studies of patientswith AIHA,10–17 prevalence of VTE
has been reported between 0 and 27% of patients (►Table 1).
Can We Predict Which Patient with AIHA Will Have
VTE?
Classical thrombotic risk factors, which are utilized in clinical
practice to decidewhen to install prophylactic anticoagulation
in medical patients,18 are frequently absent in AIHA patients
with VTE. Two studies found that the majority of VTE in AIHA
patients occurred in outpatients with a low Padua’s score.16,17
Interestingly, no constant relationshipwas foundbetweenVTE
and antiphospholipid antibodies; either they were absent or
they were transient and no thromboembolic event was regis-
tered during follow-up.10,14,15,17 In recent studies with
Fig. 1 Peripheral blood smear of the patient. Orthochromatic
erythroblast (1), normal erythrocytes (2), microspherocytes (3), and
polychromatic erythrocytes (4).
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patients with AIHA, between 88 and 100% of VTE episodes
occurred during active hemolysis (►Table 1). Regarding the
lysis parameters, several thresholds, above which the risk of a
thrombotic event is higher, have been described. Barcellini
et al, on a cohort of 308 patients, observed that VTE
was associated with pronounced anemia (hemoglobin level
80 g/L, p¼ 0.024) andwith a highermedian lactate dehydro-
genase level (837 U/L vs. 750 U/L, p¼ 0.006).15 Lecouffe-
Desprets et al found that the lowest hemoglobin level
during follow-up was lower in patients with VTE (median:
53 vs. 72 g/L, p¼ 0.016).16 Another study showed that leuko-
cyte count above 7.9 109/L (odds ratio [OR]¼ 15.7, p¼ 0.02)
and total bilirubin level of 40 µmol/L or above (OR¼ 7.4,
p¼ 0.02) were predictive for VTE in a multivariate analysis.17
Since none of these parameters has been validated in a
prospective study, caution is needed in their use in clinical
practice.
Usefulness of Anticoagulant Prophylaxis
In 2003, following three cases of fatal PE in patients with
AIHA without anticoagulant prophylaxis, Hendrick con-
ducted an audit of the effect of anticoagulant prophylaxis
in acute exacerbations of severe autoimmune hemolysis, for
which thromboembolic prophylaxis had been introduced on
a case-by-case evaluation in 1992. By reviewing a small
cohort (23 patients) of cases of AIHA hospitalized between
1986 and 2001, he found that 1 out of 21 patients with
prophylaxis had VTE versus 5 out of 15 patients without
prophylaxis.11 In the studies of Audia et al and Lecouffe-
Desprets et al, prophylactic anticoagulation was present in 2
out of 11 and 0 out of 8 patients with VTE, respectively.16,17
Despite their numerous limitations, these studies suggest
that prophylaxis is useful and, in absence of randomized
clinical trials, should be proposed in both in- and outpatients
with a flare of AIHA.
What Are the Postulated Mechanisms Predisposing to
VTE in AIHA?
Multiple mechanisms have been suggested to explain the
pathogenesis of the procoagulant condition associated with
hemolysis (►Fig. 2). RBC membrane is altered by autoanti-
bodies. This leads to an increased exposure of anionic
phospholipids, particularly phosphatidylserine (PS). The an-
ionic surface of PS promotes the assembly of enzymatic
complexes of coagulation, enhancing the conversion of co-
agulation factor X to Xa and of prothrombin to thrombin. In
sickle-cell disease, it has also been shown that PS-positive
RBCs adhere more strongly to vascular endothelium.19
Destruction of red-cell membrane also leads to the release
of microparticles (MPs). MPs that carry negatively charged
PS promote thrombin generation. Heme-laden MPs can
transfer heme to vascular endothelium and mediate oxida-
tive stress, vascular dysfunction, and occlusion.20 Destruc-
tion of erythrocytes leads also to the release in the circulation
of cell-free hemoglobin, erythrocyte arginase, free heme,
and ADP. ADP induces platelet shape change, secretion of
storage granules, influx and intracellular mobilization of
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thus promoting platelet aggregation.21 Cell-free hemoglobin
enhances the expression of adhesion molecules, such as
intracellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1), and E-selectin on endotheli-
al cells.22 Erythrocyte arginase, together with cell-free
hemoglobin, decreases nitric oxide (NO) availability by scav-
enging and decreasing its synthesis. This results in reduced
cyclic guanine monophosphate production (cGMP), leading
to impaired regulation of smooth muscle tone and platelets
activation. Finally, free heme, has per se proinflammatory
effects on endothelial cells but seems also to trigger neutro-
phil extracellular traps (NETs) formation,which recruit RBCs,
activate platelets, and promote fibrin deposition via activa-
tion of the contact phase of coagulation.23,24 Besides the
mechanisms described above, treatment itself (in particular
glucocorticoids) may contribute to the prothrombotic state
in patients with AIHA. A population-based case-control
study investigated the risk of VTE related to glucocorticoid
use by comparing 38,765 cases of VTE to 387,650 matched
controls for age and gender extracted from Danish national
registries.25 The authors found that treatment with systemic
glucocorticoids increased the risk of VTE, particularly PE.
Glucocorticoid use increased VTE risk if “present” (most
recent prescription for glucocorticoids within 90 days before
the VTE¼ adjusted incidence rate ratio [IRR]¼ 2.31; 95% CI:
2.18–2.45), “new” (first-ever prescription within 90 days
before the VTE¼ 3.06; 2.77–3.38), “continuing” (first-ever
prescription period more than 90 days before VTE¼ 2.02;
1.88–2.17), or “recent” (most recent prescription finished
between 91 and 365 days before VTE¼ 1.18; 1.10–1.26).
Furthermore, adjusted incidence rate ratio increased with
total prednisone equivalent dose.25 However, the results of
this study were not free of possible residual confounding
factors, such as an inflammatory flare, chemotherapies, or
cancer.26 Similarly, studies on the impact of glucocorticoids on
procoagulant, anticoagulant, and fibrinolytic factors showed
differential biochemical effects depending on the clinical
situation.27 For example, in healthy patients, glucocorticoids
increase factors VII, VIII, and XI activity, while during active
inflammation, glucocorticoids increased the levels of plasmin-
ogen activator-inhibitor 1 and decreased von Willebrand
factor and fibrinogen levels, thus theoretically decreasing
the prothrombotic state induced by inflammation itself. Of
note, these were not clinical outcome studies.
Perspectives
Based on the pathophysiology of thrombus formation during
AIHA,more targeted therapies tominimize the riskof bleeding
are currently explored. Erythrocyte-derived ADP induces sig-
nificant platelet activation that could be prevented by an ADP
P2Y12 receptor inhibitor. This was demonstrated, with can-
grelor, in an in vitro study ran by Gremmel et al.28 Because of
its selective importance in thrombus formation while being
dispensable forhemostasis, FXII is another interesting target.29
Moreover, FXIIa triggers inflammation through the activation
of the bradykinin-producing kallikrein-kinin system. Its inhi-
bition could have an additional anti-inflammatory effect that
could be beneficial in hemolytic anemia associated with
autoimmune conditions.29
Conclusion
To date, no guideline preconizes the introduction of an
antithrombotic prophylaxis nor the screening of VTE in
patients suffering of AIHA.
However, based on the scarce evidence in the literature and
the postulated pathophysiology of thrombosis in hemolytic
anemias, it seems reasonable to suggest a high level of suspi-
cion for VTE in patients with AIHA flare and to prescribe
anticoagulant prophylaxiswhile thepatient is exhibiting frank
hemolysis. Numerous questions are still unanswered. Should
we screen every patient with AIHA for VTE? Could D-dimer
Fig. 2 Postulated model of thrombus formation during hemolysis. Modification of RBC membrane (blue), release of intra RBC molecules
(green). ADP, adenosine diphosphate; Hb, hemoglobin; ICAM-1, intracellular adhesion molecule 1; NETs, neutrophil extracellular traps; NO,
nitric oxide; RBC, red blood cell; VCAM-1, vascular cell adhesion molecule 1.
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levels help in this decision?Are there indicators for the need of
thrombotic prophylaxis in AIHA? Which type of antithrom-
botic agent will suits best for prophylaxis and treatment,
respectively? Which duration of anticoagulation is needed?
Due to the rarity of AIHA, the responses will need prospective
multicentric studies and time. For the time being, clinicians
have to be aware of the increased thrombotic risk of AIHA
patients and individualize management decisions.
Note
Signed informed consent was obtained from the patient
included in this work.
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